Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Chiasma stock | $4.23

Learn how to easily invest in Chiasma stock.

Chiasma Inc is a biotechnology business based in the US. Chiasma shares (CHMA) are listed on the NASDAQ and all prices are listed in US Dollars. Chiasma employs 84 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Chiasma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CHMA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Chiasma stock price (NASDAQ: CHMA)

Use our graph to track the performance of CHMA stocks over time.

Chiasma shares at a glance

Information last updated 2021-10-03.
Latest market close$4.23
52-week range$2.77 - $5.00
50-day moving average $4.35
200-day moving average $3.86
Wall St. target price$9.10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.57

Buy Chiasma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Chiasma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chiasma price performance over time

Historical closes compared with the close of $4.23 from 2021-05-28

1 week (2021-10-06) N/A
1 month (2021-09-13) N/A
3 months (2021-07-16) -3.20%
6 months (2021-04-16) 44.86%
1 year (2020-10-16) 5.49%
2 years (2019-10-16) -16.90%
3 years (2018-10-16) 15.26%
5 years (2016-10-14) 63.95%

Chiasma financials

Revenue TTM $3 million
Gross profit TTM $1 million
Return on assets TTM -37.05%
Return on equity TTM -133.81%
Profit margin 0%
Book value $1.08
Market capitalisation $237.8 million

TTM: trailing 12 months

Shorting Chiasma shares

There are currently 756,012 Chiasma shares held short by investors – that's known as Chiasma's "short interest". This figure is 11% down from 849,920 last month.

There are a few different ways that this level of interest in shorting Chiasma shares can be evaluated.

Chiasma's "short interest ratio" (SIR)

Chiasma's "short interest ratio" (SIR) is the quantity of Chiasma shares currently shorted divided by the average quantity of Chiasma shares traded daily (recently around 1.2 million). Chiasma's SIR currently stands at 0.62. In other words for every 100,000 Chiasma shares traded daily on the market, roughly 620 shares are currently held short.

However Chiasma's short interest can also be evaluated against the total number of Chiasma shares, or, against the total number of tradable Chiasma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chiasma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Chiasma shares in existence, roughly 10 shares are currently held short) or 0.0224% of the tradable shares (for every 100,000 tradable Chiasma shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chiasma.

Find out more about how you can short Chiasma stock.

Chiasma share dividends

We're not expecting Chiasma to pay a dividend over the next 12 months.

Chiasma share price volatility

Over the last 12 months, Chiasma's shares have ranged in value from as little as $2.77 up to $5. A popular way to gauge a stock's volatility is its "beta".

CHMA.US volatility(beta: 1.26)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chiasma's is 1.2566. This would suggest that Chiasma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chiasma overview

Chiasma, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts. .

Chiasma in the news

There are no recent company news

Frequently asked questions

What percentage of Chiasma is owned by insiders or institutions?
Currently 0.581% of Chiasma shares are held by insiders and 76.113% by institutions.
How many people work for Chiasma?
Latest data suggests 84 work at Chiasma.
When does the fiscal year end for Chiasma?
Chiasma's fiscal year ends in December.
Where is Chiasma based?
Chiasma's address is: Building C East, Needham, MA, United States, 02494
What is Chiasma's ISIN number?
Chiasma's international securities identification number is: US16706W1027
What is Chiasma's CUSIP number?
Chiasma's Committee on Uniform Securities Identification Procedures number is: 16706W102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site